Even the most groundbreaking device won’t go far if doctors can’t easily implement that device into their practice.

MacuLogix co-founder and Chief Technology Officer Gregory Jackson, Ph.D., developed a novel instrument, AdaptDx, that could detect early-stage AMD by measuring dark adaptation speed. But it took a major design overhaul and the addition of an artificial intelligence-based testing agent named Theia for eye care doctors incorporate that device into their practices.

The current version, AdaptDx Pro, has performed over a million diagnostic tests to date. The company’s success stems from its customer-service focus and the commitment to deliver a product that’s “faster, better, smarter, cheaper,” says CEO Bill McPhee.

With host Paul Karpecki, OD, FAAO, McPhee chronicles the evolution of AdaptDx, which shrank from a 45-pound desktop instrument to a one-pound headset with a virtual assistant. They also discuss how he helped MacuLogix overcome its commercialization challenges and the lessons he learned along the way.

Listen to the podcast to discover:

• Dr. Jackson’s research, which led to the discovery of dark adaptation as a biomarker for AMD progression as well as the development of the AdaptDx prototype.
• How the physician shortage led to a subscription model and a multilingual Theia
• The marketing message that resonates with early adopters and early majority (they’re not the same).
• What led McPhee to become a six-time startup CEO.

Hit “Play” to Listen.